Raymond James Maintains Outperform on Oscar Health, Raises Price Target to $42

Raymond James analyst John Ransom has maintained an 'Outperform' rating on Oscar Health (NYSE: OSCR) and raised the price target from $34 to $42. This adjustment reflects a positive outlook for the company in the market.